...
首页> 外文期刊>PACE: Pacing and clinical electrophysiology >Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation.
【24h】

Oral loading with propafenone: a placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation.

机译:普罗帕酮的口服负荷:对近期发作的房颤的老年和非老年患者进行的安慰剂对照研究。

获取原文
获取原文并翻译 | 示例

摘要

The efficacy and safety of propafenone as an oral loading dose (600-mg single oral dose) in converting recent-onset atrial fibrillation (< or = 7 days duration) to sinus rhythm were evaluated in a single-blind, placebo-controlled study according to patients' age. Overall, 240 hospitalized patients, NYHA Class < or = 2 without signs or symptoms of heart failure were enrolled: among patients aged < or = 60 years, 55 were allocated to propafenone treatment and 59 to placebo, respectively, and among patients aged > 60 years, 64 were allocated to propafenone treatment and 62 to placebo, respectively. RESULTS: In each age group, the likelihood of conversion to sinus rhythm was significantly greater after propafenone compared with placebo at 3 and 8 hours. For patients aged < or = 60 years, corresponding odd ratios were 3.78 (95% CI = 1.80-7.92, P = 0.04) at 3 hours and 4.74 (95% CI = 2.12-10.54, P = 0.02) at 8 hours; for patients aged > 60 years odd ratios were 5.03 (95% CI = 2.08-12.12, P = 0.02) at 3 hours and 6.75 (95% CI = 3.28-73.86, P = 0.01) at 8 hours, respectively. Logistic regression analysis showed that conversion to sinus rhythm within 3 hours was predicted by age < or = 60 years (P = 0.0064) and by propafenone treatment (P < 0.0001), and conversion to sinus rhythm within 8 hours was predicted by age < or = 60 years (P = 0.0467) and by propafenone treatment (P < 0.0001). The occurrence of adverse effects was observed in 14%-16% of propafenone treated patients and in 8% of placebo treated patients without significant differences according to age. In conclusion, in patients with recent-onset atrial fibrillation without signs of heart failure, propafenone as a single oral loading dose is effective. It is also effective in selected elderly subjects with a favorable safety profile. Moreover, spontaneous conversion to sinus rhythm appears to occur less frequently in elderly patients.
机译:在单盲,安慰剂对照研究中,评估了普罗帕酮作为口服负荷剂量(单次口服剂量600 mg)将最近发作的心房颤动(持续时间≤7天)转换为窦律的功效和安全性取决于患者的年龄。总共入选了240例NYHA≤2且无心力衰竭症状或体征的住院患者:≤60岁的患者中,普罗帕酮治疗组分别分配了55名患者和安慰剂,以及60岁以上的患者中分配了59名患者。两年中,普罗帕酮治疗分别分配给64人,安慰剂分配62人。结果:在每个年龄组中,普罗帕酮后3小时和8小时相比,转换为窦律的可能性均显着高于安慰剂。对于年龄≤60岁的患者,在3小时时相应的奇数比是3.78(95%CI = 1.80-7.92,P = 0.04),在8小时时是4.74(95%CI = 2.12-10.54,P = 0.02);对于年龄大于60岁的患者,在3小时时的奇数比分别为5.03(95%CI = 2.08-12.12,P = 0.02)和8小时时为6.75(95%CI = 3.28-73.86,P = 0.01)。 Logistic回归分析表明,年龄<或= 60岁(P = 0.0064)和普罗帕酮治疗(P <0.0001)可预测3小时内窦性心律转变,年龄<或= 60岁时可预测8小时内窦性心律转变= 60年(P = 0.0467)和普罗帕酮治疗(P <0.0001)。在14%-16%的普罗帕酮治疗的患者和8%的安慰剂治疗的患者中观察到了不良反应,但没有年龄差异。总之,对于没有心力衰竭迹象的近期发作的房颤患者,普罗帕酮作为单次口服负荷剂量是有效的。在具有良好安全性的某些老年受试者中也有效。此外,在老年患者中自发转化为窦性心律的频率似乎较低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号